— Know what they know.
Not Investment Advice

GANX NASDAQ

Gain Therapeutics, Inc.
1W: -3.9% 1M: -4.5% 3M: -5.5% YTD: -46.2% 1Y: -6.0% 3Y: -46.7% 5Y: -77.0%
$1.71
-0.01 (-0.58%)
 
Weekly Expected Move ±7.2%
$1 $2 $2 $2 $2
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 31 · $72.9M mcap · 42M float · 1.73% daily turnover · Short 65% of daily vol

Balance Sheet Trends

Total Assets
$23M +88.2% ▲
5Y CAGR: +18.9%
Total Liabilities
$4M -11.1% ▼
5Y CAGR: +4.6%
Shareholders Equity
$19M +152.9% ▲
5Y CAGR: +24.5%
Cash & Investments
$21M +100.6% ▲
5Y CAGR: +22.7%
Total Debt
$732K +12.1% ▲
5Y CAGR: -10.3%
Net Debt
-$20M -106.6% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$37M$7M$12M$10M$21M
Short-Term Investments$0$13M$5M$0$0
Cash & ST Investments$37M$20M$17M$10M$21M
Net Receivables$195K$104K$243K$766K$803K
Inventory$0$0$0$0$0
Other Current Assets$0$640K$0$370K$597K
Total Current Assets$38M$21M$18M$12M$22M
Property, Plant & Equip.$1M$804K$585K$323K$409K
Goodwill & Intangibles$203K$214K$193K$134K$103K
Long-Term Investments$31K$2M$0$32K$36K
Other Non-Current Assets$53K$48K$52K$32K$34K
Total Non-Current Assets$1M$3M$830K$521K$582K
Total Assets$39M$24M$19M$12M$23M
— Liabilities —
Accounts Payable$560K$2M$1M$946K$825K
Short-Term Debt$104K$108K$119K$110K$221K
Deferred Revenue$267K$55K$1M$252K$0
Other Current Liabilities$380$364K$1M$18K$2M
Total Current Liabilities$3M$4M$5M$4M$3M
Long-Term Debt$590K$495K$449K$328K$300K
Other Non-Current Liab.$329K$158K$307K$444K$391K
Total Non-Current Liabilities$2M$1M$1M$873K$902K
Total Liabilities$4M$5M$6M$5M$4M
— Equity —
Common Stock$1K$1K$2K$3K$4K
Retained Earnings-$21M-$39M-$61M-$81M-$101M
Accumulated OCI-$91K$36K$247K-$248K$777K
Total Stockholders Equity$35M$19M$13M$7M$19M
Total Liabilities & Equity$39M$24M$19M$12M$23M
— Key Metrics —
Total Debt$2M$1M$1M$653K$732K
Net Debt-$35M-$6M-$11M-$10M-$20M
Total Investments$31K$15M$5M$32K$36K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms